Fractyl Health Inc. (GUTS) that went public as recently as February this year is currently trading around $3, a significant decline of over 75% from its initial public offering price.
The Lexington, Massachusetts-based Fractyl Health is a metabolic therapeutics company developing treatments for metabolic diseases, including Type 2 Diabetes, or T2D, and obesity.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com